EyePoint Pharmaceuticals announced the completion of the Phase 2 trial of their new experimental drug, vorolanib, for the treatment of wet age-related macular degeneration.
The purpose of the trial was to compare vorolanib to Regeneron's Eylea to determine whether vorolanib was "non-inferior" to Eylea.
The trial had 160 participants who had wet AMD who had been treated in the past with current therapies. The participants were randomized to either receive one of two vorolanib doses or Eylea. The vorolanib was given as a single intravitreal injection in a doctor's office.
Results from the Phase 2 clinical trial demonstrated that vorolanib did achieve statistical non-inferiority to the Eylea control. This means that EyePoint can now discuss their plans for a Phase 3 trial with the Food and Drug Administration and begin the trial in the second half of 2024.
